Guided Therapeutics Inc
Guided Therapeutics Inc. develops and commercializes the LuViva Advanced Cervical Scan, an electromedical device used for cervical cancer screening. The company’s business is centered on selling LuViva instruments and disposables through direct and distribution channels, while it continues to pursue regulatory approvals needed to expand commercial adoption.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueCervical cancer screening instruments sold as instrumentation packages to hospitals, clinics, and partners.
RFID chips and related consumable components used with LuViva systems.
Customers
The company sells primarily to medical distributors, healthcare systems, hospitals, and clinics that use LuViva for cervical cancer screening. It is also pursuing government and public-health buyers, including the Turkish Ministry of Health, because large-scale screening programs can create recurring demand for devices and disposables.
Buy LuViva systems for resale and market development in approved territories.
Purchase devices for cervical cancer screening programs and patient throughput.
Evaluate LuViva for public screening programs where scale and cost matter.
Buy devices for regional deployment, such as the Sulawesi hospital system in Indonesia.
Strategy
The company’s near-term strategy is to secure regulatory approvals, convert distributor relationships into shipments, and fund operations until commercialization scales. It is also trying to reduce execution risk by using external financial support, advance payments, and partner-led market entry rather than building a large direct-sales footprint too early.
Commercial scale depends on FDA and NMPA clearance, especially for the largest target markets.
The company lacks a large direct sales infrastructure, so partners are essential for market access.
The business remains loss-making and needs capital to continue operations and commercialization.
Geography
Guided Therapeutics is still a small-revenue company, but its commercial focus spans the United States, China, and Europe, with additional activity in Turkey and Indonesia. Geography matters because sales depend heavily on local regulatory approvals, distributor execution, and the timing of market access in each country.
Risks
Guided Therapeutics faces substantial regulatory, funding, and commercialization risk because its revenue base is still small and dependent on approvals that can be delayed or denied. The company also has concentration risk in a few markets and counterparties, while medical-device adoption depends on clinical acceptance, distributor performance, and manufacturing execution.
- Going concern / financing riskImpact: Critical
The company has recurring losses and needs additional capital to continue operations and fund studies.
Exposure - Regulatory approval delaysImpact: HighLikelihood: High
Sales depend on FDA and NMPA clearance, and delays directly push out revenue and cash generation.
Exposure: LuViva commercialization in the U.S. and China
- Distributor and counterparty riskImpact: High
Sales depend on partners such as SMI, Newmars, and HDMT, and one partner is in contractual default.
Exposure - Market acceptance riskImpact: High
The product must gain clinical and commercial acceptance versus existing cervical screening methods.
Exposure - Geopolitical and country-specific market riskImpact: MediumLikelihood: High
Russia and other markets may face approval, trade, or operating constraints.
Exposure: European distribution and international expansion
Accounting
Judgemental itemsSome customer payments are recorded as deferred revenue until shipment or approval conditions are met.
Impact: Can shift revenue between quarters and affect comparability.
The company reported a sizable deferred revenue balance tied to future shipments.
Impact: Indicates revenue already billed or collected but not yet recognized.
Devices and components must be written down if demand or approval timing changes.
Impact: Can affect gross margin and operating results.
Employee, service-provider, and investor instruments are valued using option-pricing models.
Impact: Can create non-cash expense volatility.
Similar listed companies
Publicly listed companies with a comparable business focus.
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Cadrenal Therapeutics, Inc.
CVKD · Pharmaceutical Preparations
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
LivaNova PLC
LIVN · Electromedical & Electrotherapeutic Apparatus
LivaNova PLC is a medical technology company focused on therapies for cardiac and neurological conditions.
Last updated: 24/09/2026